Baseline glucagon impacts glucose-lowering effects of acarbose but not metformin: A sub-analysis of MARCH study
Authors' conclusion
Higher baseline glucagon significantly enhanced the glucose-lowering efficacy of acarbose but not metformin, suggesting glucagon could guide personalized diabetes treatment.
Study context
- Population
- Patients with newly diagnosed T2D
- Participants
- 493 patients
- Comparison
- Acarbose vs metformin, by baseline glucagon tertile
- Primary endpoint
- Change in HbA1c
- Follow-up
- 24 and 48 weeks
Methodological detailssubgroup analysis by baseline glucagon tertiles
- Subgroup analysis by baseline glucagon tertiles
Primary result
As reported in the abstract
Change in HbA1c with acarbose, by baseline glucagon tertile
- Acarbose: higher baseline glucagon correlated with greater hemoglobin A1c (HbA1c) reductions
- Metformin: consistent glucose-lowering effects across all glucagon subgroups
- High glucagon vs Low glucagon: P < 0.05
- Medium glucagon vs Low glucagon: P < 0.05
Further findings
HbA1c change overall · 24 and 48 weeks
- Significant HbA1c reductions with both acarbose and metformin
Original publication
Baseline glucagon impacts glucose-lowering effects of acarbose but not metformin: A sub-analysis of MARCH study. Diabetes Res Clin Pract. Published 2 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →